Cobra Biologics, a CDMO focused on advanced therapy medicinal products (ATMPs) has won a £1.5 million shared grant from Innovate UK. Along with Pall Corp., a filtration, separation and purification provider, and the Cell and Gene Therapy Catapult, an independent research organization, the companies will work to investigate continuous manufacturing of adeno-associated virus (AAV) for gene therapy applications.  “In light of the unprecedented clinical successes with a number of ATMPs, we are lo...